Abstract
Objective: Although high dose gammaglobulin (IVGG) associated with aspirin became the standards in the therapy for Kawasaki disease (KD), the coronary complications still occur about 10 percent of all KD patients. We report five cases of KD successfully treated with FOY which is recently found to be effective in SIRS by suppressing the production of inflammatory cytokines in addition to IVGG and aspirin. Methods: We gave FOY in five KD cases aged 7 mo. to 3 y/o admitted consecutively in January to April 2001 in our hospital with informed consent. Four patients were at high risk group who needed to be given IVGG total dose of 2g/kg and one patient was at low risk group. FOY was given intravenously to all patients with continuous dose in 1-2mg/kg/hr.Results: FOY was effective in decreasing each body temperature, white blood cell counts, and CRP. Four cases were cured with FOY without the coronary complications. The coronary complications occurred in only one case who had admitted on 9th day and the dilatation of the coronary was seen on the day of admission, however even in this severe case with early coronary dilatation, no progress was seen after treatments. FOY showed no side effects in all five cases.Conclusions: We believe FOY in addition to IVGG and aspirin was effective in our all five cases. Although further case controlled studies are needed, FOY could be expected to be a new additional therapy for preventing the coronary complications of KD.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Okafuji, T., Sakaguchi, N., Usui, N. et al. Gabexate Mesilate (FOY) as a New Additional Therapy to High Dose Intravenous Gammaglobulin for High Risk Kawasaki Disease. Pediatr Res 53, 182 (2003). https://doi.org/10.1203/00006450-200301000-00172
Issue Date:
DOI: https://doi.org/10.1203/00006450-200301000-00172